Progress toward a staphylococcus aureus vaccine

Clinical Infectious Diseases

Volumn 54, Issue 4, 2012, Pages 560-567

  Daum, Robert S ^a   Spellberg, Brad ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; ALPHA HEMOLYSIN; BACTERIAL PROTEIN; N ACETYLGLUCOSAMINE; PAGIBAXIMAB; PANTON VALENTINE LEUKOCIDIN; POLY N ACETYLGLUCOSAMINE; POLYSACCHARIDE; PROTEIN ISDB; STAPHYLOCOCCUS PROTEIN A; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; AMERICAN INDIAN; ANTIBIOTIC RESISTANCE; ARTICLE; ATHLETE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CYSTIC FIBROSIS; DISEASE TRANSMISSION; DRUG FORMULATION; DRUG TOLERABILITY; HEART SURGERY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NASOPHARYNX; NECROTIZING FASCIITIS; NONHUMAN; OSTEOMYELITIS; PACIFIC ISLANDER; PASSIVE IMMUNIZATION; PHAGOCYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLDIER; STAPHYLOCOCCAL BACTEREMIA; STERNOTOMY; T LYMPHOCYTE; UNITED STATES; VACCINATION;

ANTIGENS, BACTERIAL; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 84856699411     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir828     Document Type: Article

References (50)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
2. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23:616-87.
3. Crawford S, Boyle-Vavra S,DaumR. Community associated methicillinresistant Staphylococcus aureus. In: Hooper DC, ScheldWM, Hughes JM, eds. Emerging infections 7. 2007: 153-79.
4. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-1.
5. Liu C, Graber CJ, Karr M, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis 2008; 46:1637-46. (Pubitemid 351706759)
6. Morrison-Rodriguez SM, Pacha LA, Patrick JE, Jordan NN. Community-associated methicillin-resistant Staphylococcus aureus infections at an Army training installation. Epidemiol Infect 2010; 138:721-9.
7. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-41.
8. Howden BP, Davies JK, Johnson PD, Stinear TP, ML G. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycinintermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23:99-139.
9. Périchon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Ch 2009; 53:4580-7.
10. Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Ch 2009; 53:5265-74.
11. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Ch 2008; 52:2244-6. (Pubitemid 351758569)
12. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
13. Cadilla A, David MZ, Daum RS, Boyle-Vavra S. Association of high-level mupirocin resistance and multidrug-resistant methicillinresistant Staphylococcus aureus at an academic center in the Midwestern United States. J Clin Micro 2010; 49:95-100.
14. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010; 304:641-8.
15. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6. (Pubitemid 34441740)
16. Shapiro CN, HS M. Hepatitis B epidemiology and prevention. Epidemiol Rev 1990; 12:221-7.
17. Centers for Disease Control and Prevention. A Comprehensive immunization strategy to eliminate transmission of hepatitis B Virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of infants, children and adolescents. MMWR Recomm Rep 2005; 54:1-23.
18. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus-United States. MMWR Morb Mortal Wkly Rep 1981; 30:557-9.
19. Lee CJ, Sankaran S, Mukherjee DV, et al. Staphylococcus aureus oropharyngeal carriage in a prison population. Clin Infect Dis 2011; 52:775-8.
20. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia: Study Group. N Engl J Med 2001; 344:11-6. (Pubitemid 32064839)
21. Adem P, Montgomery C, Husain A, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. New Engl J Med 2005; 353:1245-51. (Pubitemid 41345946)
22. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related communityacquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37:1050-8. (Pubitemid 37323659)
23. Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005; 40:941-7. (Pubitemid 40418298)
24. Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005; 41:583-90. (Pubitemid 41170343)
25. Bocchini CE, Hulten KG, Mason EO Jr, Gonzalez BE,HammermanWA, Kaplan SL. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 2006; 117:433-40. (Pubitemid 46071606)
26. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445-53. (Pubitemid 40471452)
27. Verdier I, Durand G, Bes M, et al. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests. 2007; 45:725-9.
28. Montgomery CP, Boyle-Vavra S, Adem P, et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 2008; 198:561-70.
29. Maira-Litran T, Kropec A, Abeygunawardana C, et al. Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect Immun 2002; 70:4433-40. (Pubitemid 34790954)
30. Cramton SE, Gerke C, Schnell NF, NicholsWW, Götz F. The intercellular adhesin (ica) locus is present in Staphylococcus aureus and required for biofilm formation. Infect Immun 1999; 67:5427-33. (Pubitemid 29455321)
31. Heilman C, Schweitzer O, Gerke C, Schnell NF, Nichols WW, Götz F. Molecular basis of intercellular adhesion in the biofilm forming Staphylococcus epidermidis. Mol Microbiol 1996; 20:1083-91. (Pubitemid 26198280)
32. Vuong C, Kocianova S, Voyich JM, et al. A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion and virulence. J Biol Chem 2004; 279:54881-6. (Pubitemid 40053234)
33. Cerca N, Jefferson K, Maira-Litran T, et al. Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 2007; 75:3401-13.
34. Kelly-Quintos C, Kropec A, Briggs S, Ordonez CL, Goldmann DA, Pier GB. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis 2005; 192:2012-9. (Pubitemid 41681901)
35. Maira-Litran T, Kropec A, Goldmann DA, Pier GB. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 2005; 73:6752-62. (Pubitemid 41368842)
36. Kuklin NA, Clark DJ, Secore S, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74:2215-23.
37. Kaufman D. Veronate (Inhibitex). Curr Opin Investig Drugs 2006; 7:172-9.
38. Brown EL, Dumitrescu O, Thomas D, et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infec 2009; 15:156-64.
39. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008; 205:287-94. (Pubitemid 351281594)
40. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006; 103:16942-7. (Pubitemid 44737357)
41. Goodyear CS, Silverman GJ. B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies. Springer Sem Immun 2005; 26:463-84. (Pubitemid 40468897)
42. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 2010; 207:1863-70.
43. Spellberg B, Ibrahim AS, Yeaman MR, et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 2008; 76:4574-80.
44. Lin L, Ibrahim AS, Baquir B, Avanesian V, Fu Y, Spellberg B. Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol MedMic 2009; 55:293-5. Epub 2009 Jan 13.
45. Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703.
46. Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009; 30:108-19.
47. Cho JS, Pietras EM, Garcia NC, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010; 120:1762-3.
48. Pachl J, Svoboda P, Jacobs F, et al. Mycograb Invasive Candidiasis Study Group: A randomized, blinded,multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42:1404-13.
49. Torosantucci A, Bromuro C, Chiani P, et al. A novel glycoconjugate vaccine against fungal pathogens. J Exp Med 2005; 202: 597-606. (Pubitemid 41258184)
50. Torosantucci A, Chiani P, Bromuro C, et al. Protection by anti-betaglucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 2009; 4:e5392 Epub 2009 Apr 28.